PI3K Modulators Targeting Class I Enzymes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors lack specificity and are nonspecific, leading to challenges in effectively targeting Class I PI3K enzymes, which are implicated in various cancers and diseases, and there is a need for more targeted kinase modulators to regulate kinase activity.
Innovation Solution
Development of specific PI3K protein kinase modulators, including compounds with specific chemical structures that can inhibit PI3K enzymes, particularly targeting Class I PI3K, to treat diseases associated with kinase-mediated events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonspecific PI3K inhibitors are used, then kinase activity can be inhibited, but specificity is poor leading to off-target effects
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that target particular regions or characteristics of Class I PI3K enzymes. The compounds possess distinct structural elements (such as specific heterocyclic groups, substitution patterns, and molecular configurations) that enable selective binding to Class I PI3K isoforms while avoiding other kinase families, thereby achieving high specificity and reducing off-target effects.
Solution Approach 2:
The patent employs parameter changes by optimizing various molecular parameters of the inhibitor compounds including molecular weight, hydrophobicity, electrostatic properties, and spatial configuration. By carefully adjusting these parameters within specific ranges, the inhibitors achieve optimal selectivity for Class I PI3K enzymes while maintaining adequate potency, thus resolving the contradiction between inhibition effectiveness and specificity.
2Adaptability or versatility
If broad-spectrum kinase inhibitors are used, then multiple kinase targets are inhibited, but therapeutic precision is reduced
Solution Approach 1:
The patent applies segmentation by dividing the kinase inhibitor market into specific target classes. Instead of developing broad-spectrum inhibitors that affect multiple kinase families, the invention focuses specifically on Class I PI3K enzymes, segmenting the therapeutic approach to achieve precision medicine goals while still addressing the unmet need for effective PI3K inhibition in cancer therapy.
3Reliability
If existing PI3K inhibitors are used, then kinase-mediated disease processes can be targeted, but side effects increase due to nonspecificity
Solution Approach 1:
The patent converts the potential harm of off-target kinase inhibition into a benefit by designing inhibitors that exploit the unique structural features of Class I PI3K enzymes. The compounds are engineered to have high selectivity for this specific enzyme class, thereby converting what would be harmful nonspecificity into a beneficial selective therapeutic action that targets disease processes while minimizing side effects.
Data Source
AI summary
The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.